Purpose:
Our study examined whether T2DM and glucocorticoids treatment
affect bone quality and quantity that are measured by Bone Mineral
Density (BMD) and Trabecular Bone Score (TBS).
Materials & methods:
Participants in this study were 2294 women and men aged over 60
years who participated in stage II of the Bushehr Elderly Health (BEH)
program. Patients with T2DM and those who received glucocorticoids were
included. BMD was detected using the DXA method and the TBS of L1-L4 was
evaluated by TBS iNsight® software. To evaluate the correlation between
TBS and BMD levels with diabetes and taking corticosteroids
sex-specific multivariable linear regression models were appplied.
Results:
TBS and BMD were not significantly different in those who had
received glucocorticoids versus those who did not.T2DM revealed a
significant association with both BMD and TBS in men (beta = 0.12, p
< 0.001 and beta = 0.063, p = 0.03, respectively). BMD values were
significantly higher in diabetic women (beta = 0.073, p < 0.01). BMI
had a significant association with both TBS and BMD but in an opposite
direction, in women and men (BMD: beta = -0.22, -0.24, and regarding
TBS: beta = 0.37, 0.25, all p-values < 0.001).
Conclusion:
Our findings showed that T2DM had major effects on BMD in both men
and women. However, T2DM only affects TBS in men. Furthermore, neither
BMD nor TBS were affected by GC intake in men or women.Based on the
variable importance of covariates, BMI was the most influential factor
on both BMD and TBS, although in opposite directions, in both sexes.